
USD
$0.00
(0.00%
)At Close (As of Dec 12, 2025)
$4.21B
Market Cap
-
P/E Ratio
-2.12
EPS
$48.55
52 Week High
$18.92
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | -$346K |
| Total Revenue | $0 |
| Cost Of Revenue | $346K |
| Costof Goods And Services Sold | $346K |
| Operating Income | -$151M |
| Selling General And Administrative | $49M |
| Research And Development | $102M |
| Operating Expenses | $151M |
| Investment Income Net | - |
| Net Interest Income | $41M |
| Interest Income | $41M |
| Interest Expense | $94K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $346K |
| Income Before Tax | -$110M |
| Income Tax Expense | -$110M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$110M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$151M |
| Ebitda | -$151M |
| Net Income | -$110M |
| Field | Value (USD) |
|---|---|
| Gross Profit | -$346K |
| Total Revenue | $0 |
| Cost Of Revenue | $346K |
| Costof Goods And Services Sold | $346K |
| Operating Income | -$151M |
| Selling General And Administrative | $49M |
| Research And Development | $102M |
| Operating Expenses | $151M |
| Investment Income Net | - |
| Net Interest Income | $41M |
| Interest Income | $41M |
| Interest Expense | $94K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $346K |
| Income Before Tax | -$110M |
| Income Tax Expense | -$110M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$110M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$151M |
| Ebitda | -$151M |
| Net Income | -$110M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California, dedicated to developing innovative therapies for metabolic and endocrine disorders. With a focus on addressing pressing unmet medical needs, including obesity and liver disease, the company's promising pipeline features novel drug candidates poised to transform patient care. Leveraging proprietary drug development platforms and deep expertise in metabolic pathways, Viking Therapeutics aims to significantly enhance patient outcomes and establish a strong presence in the biopharmaceutical industry as it advances through clinical trials.